Servier's Tibsovo snags FDA combo nod in first-line AML, expanding its use in tough-to-treat cancer
May 26, 2022
Servier’s Tibsovo snags FDA combo nod in first-line AML, expanding its use in tough-to-treat cancer
esagonowsky
Thu, 05/26/2022 – 10:03
Source link